MoonLake Immunotherapeutics Quarterly Balance Sheet
NASDAQ: MLTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MoonLake Immunotherapeutics financial position
As of Jun 30, 2026, MoonLake Immunotherapeutics reported total assets of $573.9 million, up 24.7% from a year earlier against total liabilities of $145.8 million. Shareholders' equity stood at $428.2 million, or 74.6% of assets. The company held $477.9 million in cash and equivalents against $99.5 million of debt, a net cash position of $378.4 million.
The current ratio (current assets divided by current liabilities) was 12.56, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.23.
Summary generated from market data by MetaCap's automated system. Methodology
MoonLake Immunotherapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 477.90M | 298.49M | 334.52M | 350.74M | 306.68M | 271.57M | 180.43M | 375.66M | 342.79M | 458.44M | 451.17M | 318.17M |
| Short-Term Investments | 59.13M | 59.43M | 59.45M | 29.74M | 118.40M | 208.56M | 267.60M | 118.27M | 177.01M | 88.61M | 59.84M | 177.81M |
| Total Current Assets | 570.04M | 396.64M | 421.69M | 411.21M | 455.48M | 506.26M | 474.29M | 512.32M | 536.88M | 553.59M | 514.17M | 500.01M |
| Property, Plant & Equipment | 487.00K | 532.00K | 577.00K | 622.00K | 667.00K | 711.00K | 722.00K | 581.38K | 481.70K | 509.82K | 320.87K | 39.52K |
| Total Assets | 573.95M | 400.37M | 424.43M | 414.33M | 460.10M | 511.26M | 477.93M | 518.21M | 544.88M | 564.12M | 526.54M | 500.22M |
| Total Current Liabilities | 45.39M | 46.11M | 45.48M | 48.37M | 27.36M | 23.98M | 22.46M | 20.08M | 12.28M | 8.91M | 9.97M | 10.31M |
| Long-Term Debt | 99.51M | 99.02M | 74.10M | 73.74M | 73.38M | 73.02M | 0 | — | — | — | — | — |
| Total Liabilities | 145.75M | 146.35M | 119.95M | 123.14M | 102.15M | 98.68M | 24.54M | 22.71M | 14.85M | 11.73M | 13.05M | 10.58M |
| Shareholders' Equity | 428.19M | 254.02M | 304.48M | 288.91M | 353.73M | 407.52M | 446.82M | 488.20M | 520.66M | 542.55M | 495.68M | 424.93M |
| Retained Earnings | -594.42M | -532.62M | -462.91M | -400.49M | -330.76M | -275.54M | -235.59M | -189.99M | -154.60M | -130.33M | -116.66M | -109.22M |
| Total Debt | 99.51M | 99.02M | 74.10M | 73.74M | 73.38M | 73.02M | 0 | — | — | — | — | — |
| Net Cash (Debt) | 437.52M | 258.90M | 319.87M | 306.74M | 351.70M | 407.11M | 448.03M | 493.92M | 519.80M | 547.05M | 511.01M | 495.98M |
This table shows 12 quarterly periods of MoonLake Immunotherapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow MLTX's reporting calendar. What is a balance sheet?